title: Influence of H. pylori infection on meal-stimulated gastric acid secretion and gastroesophageal acid reflux.
abstract: Gastric acid secretion, gastrin release, gastric emptying, and gastroesophageal acid reflux were measured in asymptomatic individuals before and after elimination of Helicobacter pylori gastritis. After basal gastric acid secretion and serum gastrin concentrations were measured, meal-stimulated gastric acid secretion and gastrin release were assessed during in vivo intragastric titration to pH 3. Experiments were repeated 4 wk after treatment with lansoprazole, amoxicillin, and clarithromycin. Esophageal pH was also monitored for 24 h before and after therapy. Basal gastric acidity increased approximately 20 mmol/l in subjects whose infection was eradicated (P < 0.05) but not in those with persistent infection. Basal and meal-stimulated gastric acid secretion did not change after H. pylori eradication, despite a 41% reduction in meal-stimulated gastrin release (P < 0.05). Gastroesophageal acid reflux increased two- to threefold after successful treatment (P < 0. 05) but did not change in subjects with persistent infection. Thus elimination of H. pylori gastritis increases gastric acidity, probably by reducing nonparietal alkaline secretion, and this may facilitate gastroesophageal acid reflux.
authors.affiliation: Department of Internal Medicine, Department of Veterans Affairs, North Texas Health Care System, Dallas 75216, USA.
authors.forename: M
authors.initials: M
authors.lastname: Feldman
authors.forename: B
authors.initials: B
authors.lastname: Cryer
authors.forename: D
authors.initials: D
authors.lastname: Sammer
authors.forename: E
authors.initials: E
authors.lastname: Lee
authors.forename: S J
authors.initials: SJ
authors.lastname: Spechler
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000658:Amoxicillin / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000897:Anti-Ulcer Agents / Q000494:pharmacology; D017291:Clarithromycin / Q000494:pharmacology; D004941:Esophagitis / Q000378:metabolism / Q000382:microbiology; D005260:Female; D005502:Food; D005744:Gastric Acid / Q000378:metabolism*; D005746:Gastric Emptying / Q000502:physiology; D005753:Gastric Mucosa / Q000378:metabolism / Q000382:microbiology*; D005755:Gastrins / Q000097:blood; D005756:Gastritis / Q000378:metabolism / Q000382:microbiology; D005764:Gastroesophageal Reflux / Q000378:metabolism / Q000382:microbiology*; D016481:Helicobacter Infections / Q000188:drug therapy / Q000378:metabolism*; D016480:Helicobacter pylori; D006801:Humans; D006863:Hydrogen-Ion Concentration; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D009853:Omeprazole / Q000031:analogs & derivatives / Q000494:pharmacology; D010406:Penicillins / Q000494:pharmacology; D011092:Polyethylene Glycols; D019518:Postprandial Period; D012997:Solvents
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D005755:Gastrins; D010406:Penicillins; D012997:Solvents; D064747:Lansoprazole; D011092:Polyethylene Glycols; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole